Skip to content
  • Tuesday, 29 September 2026
  • 12:12 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jul 5, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 27, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 20, 2026 0

Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 13, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…

Read More
Science News: Empowering Public Understanding of Science for Over a CenturyJapan Emerges as a Global Powerhouse for Regenerative Medicine InnovationShigellosis Vaccine Shows Promise in Combating Antibiotic-Resistant BacteriaChallenges to the Centaur Model Highlight Persistent Gaps Between Artificial Intelligence and Human Cognitive Processes
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must Have
Dual-Drug Therapy Breakthrough Offers New Hope for Acute Myelogenous Leukemia Patients in Landmark Ludwig Cancer Research StudyMolten Salt Breakthrough: Oak Ridge Researchers Convert Common Plastic Waste Into Gasoline and Diesel at Low TemperaturesDaiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA DiscussionsScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Dual-Drug Therapy Breakthrough Offers New Hope for Acute Myelogenous Leukemia Patients in Landmark Ludwig Cancer Research Study
Dwi Wanna Sep 29, 2026
Advanced Materials Science
Molten Salt Breakthrough: Oak Ridge Researchers Convert Common Plastic Waste Into Gasoline and Diesel at Low Temperatures
Nila Kartika Wati Sep 29, 2026
Pharmaceutical R&D
Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions
Teuku Ryan Sep 29, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 29, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ